Jazz Pharmaceuticals Licenses PharmaMar’s Lung Cancer Drug Lurbinectedin
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)
Published: 24 Dec-2019
DOI: 10.3833/pdr.v2019.i12.2479 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to expand its oncology portfolio, Jazz Pharmaceuticals has agreed to license the US rights todevelop and commercialise lurbinectedin from PharmaMar in a deal worth up to US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS